TP53 and neoplasm: Several tumour‐derived p53 mutations are gain‐of‐function mutations and act as driver oncogenes promoting metastatic dissemination and drug resistance (Alexandrova et al., 2017; Amelio et al., 2018; Kim and Lozano, 2018; Morrison et al., 2017; Muller and Vousden, 2014; Parrales et al., 2018; Vaughan et al., 2017).